Selinexor Market Summary

Key Factors Driving Selinexor Growth

1. Positive Phase III SENTRY trial strengthens regulatory pathway and commercial potential

Selinexor, an oral selective inhibitor of exportin-1 (XPO1), is being developed in combination with ruxolitinib as a frontline treatment for JAK inhibitor-naïve myelofibrosis (MF). In 2026, Karyopharm announced that the pivotal Phase III SENTRY (XPORT-MF-034) trial met one of its two co-primary endpoints, demonstrating a statistically significant improvement in ≥35% spleen volume reduction (SVR35) at Week 24 compared with ruxolitinib alone. Although the study did not achieve statistical significance for the total symptom score (TSS) endpoint, the positive spleen efficacy and favorable safety profile support continued regulatory discussions and reinforce selinexor's potential role in frontline MF.

2. Differentiated mechanism offers potential disease-modifying activity

Unlike JAK inhibitors, selinexor inhibits XPO1-mediated nuclear export, restoring the activity of tumor suppressor proteins such as p53, p21, and FOXO, while suppressing NF-κB signaling. Preclinical and early clinical studies suggest that this mechanism may reduce malignant hematopoietic stem cells and improve bone marrow biology rather than simply controlling symptoms. Phase I/II studies combining selinexor with ruxolitinib demonstrated improvements across spleen volume, symptom burden, and biomarkers associated with disease modification, providing a strong scientific rationale for continued development.

3. Combination therapy addresses a significant unmet need in frontline myelofibrosis

Despite the availability of approved JAK inhibitors, many patients experience inadequate spleen responses, persistent constitutional symptoms, or progressive disease over time. Selinexor is positioned as an add-on therapy to ruxolitinib, aiming to deepen treatment responses without replacing the existing standard of care. The Phase III SENTRY trial enrolled 353 JAK inhibitor-naïve patients, reflecting a substantial addressable population if the combination ultimately gains regulatory approval. The combination strategy is expected to facilitate physician adoption by building upon an established treatment backbone.

4. Encouraging early clinical data support broader physician confidence

Earlier Phase I and Phase II studies demonstrated clinically meaningful activity with selinexor in MF. Karyopharm reported improvements in spleen volume reduction, symptom improvement, stabilization of hemoglobin, and potential biomarkers of disease modification. In the randomized XPORT-MF-035 Phase II study involving heavily pretreated patients, selinexor also showed favorable trends in maintaining hemoglobin levels and reducing transfusion requirements compared with physician's choice therapy, supporting continued interest in the molecule beyond frontline treatment.

5. Global commercial infrastructure and expanding international presence

Selinexor is already marketed as XPOVIO® for multiple myeloma and diffuse large B-cell lymphoma, providing Karyopharm with an established commercial infrastructure. By early 2026, selinexor had received approvals in more than 50 countries, with additional reimbursement approvals in markets such as Spain and China. Existing physician familiarity, commercial channels, and international partnerships should facilitate rapid uptake if the MF indication is approved.

Selinexor Recent Developments

In July 2026, Karyopharm Therapeutics announced that it plans to submit a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) in August 2026 seeking accelerated approval of selinexor in combination with ruxolitinib for the treatment of patients with myelofibrosis.

“Selinexor Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Selinexor for approved indication like Diffuse large B cell lymphoma and Multiple myeloma; as well as potential indication like Endometrial cancer, Liposarcoma, Myelofibrosis, Acute myeloid leukaemia, Myelodysplastic syndromes, Malignant melanoma, Ovarian cancer and Colorectal cancer in the 7MM. A detailed picture of Selinexor’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Selinexor for approved and potential indications. The Selinexor market report provides insights about Selinexor’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Selinexor performance, future market assessments inclusive of the Selinexor market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Selinexor sales forecasts, along with factors driving its market.

Selinexor Drug Summary

Selinexor (marketed as XPOVIO) is a first-in-class, orally administered selective inhibitor of nuclear export (SINE) that targets exportin 1 (XPO1), leading to the nuclear retention and reactivation of tumor suppressor proteins and induction of apoptosis in malignant cells. Selinexor is approved for the treatment of multiple hematologic malignancies, including multiple myeloma and relapsed or refractory diffuse large B-cell lymphoma (DLBCL), and is also being investigated in several other cancers, including myelofibrosis, where it has been evaluated in combination with the JAK inhibitor ruxolitinib. Administered orally once or twice weekly depending on the indication, selinexor has demonstrated antitumor activity through its novel mechanism of restoring tumor suppressor function and reducing oncogenic signaling. In myelofibrosis, early-phase clinical studies have shown encouraging improvements in spleen volume reduction, symptom burden, and treatment durability when combined with ruxolitinib in JAK inhibitor–naïve patients. The most common adverse events include nausea, fatigue, decreased appetite, thrombocytopenia, anemia, hyponatremia, and neutropenia, necessitating careful monitoring and supportive care. Although approved for multiple myeloma and DLBCL, selinexor remains an investigational therapy for myelofibrosis and continues to be evaluated in clinical trials for its potential to improve outcomes in this disease. The report provides Selinexor’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Selinexor Market Report

The report provides insights into:

• A comprehensive product overview including the Selinexor MoA, description, dosage and administration, research and development activities in approved indications like Diffuse large B cell lymphoma and Multiple myeloma; as well as potential indication like Endometrial cancer, Liposarcoma, Myelofibrosis, Acute myeloid leukaemia, Myelodysplastic syndromes, Malignant melanoma, Ovarian cancer and Colorectal cancer.
• Elaborated details on Selinexor regulatory milestones and other development activities have been provided in Selinexor market report.
• The report also highlights Selinexor‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The Selinexor market report also covers the patents information, generic entry and impact on cost cut.
• The Selinexor market report contains current and forecasted Selinexor sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Selinexor market report also features the SWOT analysis with analyst views for Selinexor in approved and potential indications.

Methodology

The Selinexor market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Selinexor Analytical Perspective by DelveInsight

• In-depth Selinexor Market Assessment

This Selinexor sales market forecast report provides a detailed market assessment of Selinexor for approved indication like Diffuse large B cell lymphoma and Multiple myeloma; as well as potential indication like Endometrial cancer, Liposarcoma, Myelofibrosis, Acute myeloid leukaemia, Myelodysplastic syndromes, Malignant melanoma, Ovarian cancer and Colorectal cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Selinexor sales data uptil 2034.

• Selinexor Clinical Assessment

The Selinexor market report provides the clinical trials information of Selinexor for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Selinexor Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Selinexor Market Potential & Revenue Forecast

• Projected market size for the Selinexor and its key indications
• Estimated Selinexor sales potential (Selinexor peak sales forecasts)
• Selinexor Pricing strategies and reimbursement landscape

Selinexor Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Selinexor Market positioning compared to existing treatments
• Selinexor Strengths & weaknesses relative to competitors

Selinexor Regulatory & Commercial Milestones

• Selinexor Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Selinexor Clinical Differentiation

• Selinexor Efficacy & safety advantages over existing drugs
• Selinexor Unique selling points

Selinexor Market Report Highlights

• In the coming years, the Selinexor market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Selinexor companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Selinexor’s dominance.
• Other emerging products for Diffuse large B cell lymphoma and Multiple myeloma; as well as potential indication like Endometrial cancer, Liposarcoma, Myelofibrosis, Acute myeloid leukaemia, Myelodysplastic syndromes, Malignant melanoma, Ovarian cancer and Colorectal cancer are expected to give tough market competition to Selinexor and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Selinexor in approved and potential indications.
• Analyse Selinexor cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Selinexor sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Selinexor in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Selinexor? How strong is Selinexor’s clinical and commercial performance?
• What is Selinexor’s clinical trial status in each individual indications such as Diffuse large B cell lymphoma and Multiple myeloma; as well as potential indication like Endometrial cancer, Liposarcoma, Myelofibrosis, Acute myeloid leukaemia, Myelodysplastic syndromes, Malignant melanoma, Ovarian cancer and Colorectal cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Selinexor Manufacturers?
• What are the key designations that have been granted to Selinexor for approved and potential indications? How are they going to impact Selinexor’s penetration in various geographies?
• What is the current and forecasted Selinexor market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Selinexor in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Selinexor for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is Selinexor? What is the duration of therapy and what are the geographical variations in cost per patient?